Insmed reported a narrower Q1 loss and revenue of $306.0 million, above the FactSet consensus of $300.8 million, though some coverage reported a revenue miss against other estimates. The stock closed down about 23% on May 7 as investors eyed guidance. Although Insmed beat analyst expectations in one of the metrics, the results and overall sentiment led to selling pressure.

Insmed (INSM) released its quarterly earnings for the period ending March 31, 2026, reporting a Q1 loss. Revenue of $306.0 million came in above the FactSet consensus of $300.8 million, although some coverage reported it as a miss against other estimates. The stock closed down about 23% on May 7, from $137.09 to $105.00, after early reports of a 6% decline. Despite the loss being narrower than expected, the market's response suggests investors remain cautious about the company's financials.

Insmed also reported beating earnings per share expectations. The selling began in pre-market hours, with coverage pointing to concerns over the forward-looking guidance.

The reaction from investors suggests that there may be ongoing questions about Insmed's ability to meet revenue targets going forward. Market participants will likely closely examine the company's subsequent updates for improved guidance or growth plans.

Insmed Reports Narrower Q1 Loss, Shares Slide on Market Reaction